JT:6869 Sysmex Corporation
Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, sale, and export/import of diagnostic instruments, reagents, and related software for the use in hematology, urinalysis, immunochemistry, clinical chemistry, and hemostasis. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; systems for high-volume testing in labs; and hematology analyzers for animals. The company also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for to test for liver fibrosis progression and atopic dermatitis; and support services for hemostasis products. In addition, it offers systems for the detection of cancer lymph node metastasis; cytogenic testing services; and lab assay services. It serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. The company operates in the Americas, Europe, the Middle East, Africa, the Asia Pacific, China, and Japan. Sysmex Corporation has a collaboration with MolecularMD Corporation to develop and commercialize companion diagnostics; and a strategic collaboration with Biolidics Limited for the development of laboratory assays in the field of circulating tumor cells. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.This company has ADRs that trade in the U.S. as the symbol SSMXY.
8,401.00 JPY
As of 03/24/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry:
Index country: Japan
Country of incorporation: Japan
IPO date: 07/25/1996
Stock exchange: Tokyo Stock Exchange
Exchange country: Japan
Market cap: 0 JPY
Current dividend yield: 0.00%
Sedol: 6883807